ClinicalTrials.gov record
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
ClinicalTrials.gov ID: NCT00168779
Public ClinicalTrials.gov record NCT00168779. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to compare the effectiveness of telmisartan 80 mg / hydrochlorothiazide 25 mg \[Micardis HCT\] to valsartan 160 mg / hydrochlorothiazide 25 mg \[Diovan HCT\] and placebo in the treatment of Stage 1 and Stage 2 hypertension.
Study identification
- NCT ID
- NCT00168779
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 1,185 participants
Conditions and interventions
Conditions
Interventions
- telmisartan 80 mg / hydrochlorothiazide 25 mg Drug
- valsartan 160 mg / hydrochlorothiazide 25 mg Drug
- placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2005 (Type not available)
- Primary completion
- Jul 2006 (Actual)
- Completion
- Jul 2006 (Actual)
- Last update posted
- Dec 28, 2017
2005 – 2006
United States locations
- U.S. sites
- 113
- U.S. states
- 34
- U.S. cities
- 93
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 502.476.074 Boehringer Ingelheim Investigational Site | Athens | Alabama | — | — |
| 502.476.059 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 502.476.071 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 502.476.079 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 502.476.014 Boehringer Ingelheim Investigational Site | Huntsville | Alabama | — | — |
| 502.476.031 Boehringer Ingelheim Investigational Site | Huntsville | Alabama | — | — |
| 502.476.110 Boehringer Ingelheim Investigational Site | Huntsville | Alabama | — | — |
| 502.476.037 Boehringer Ingelheim Investigational Site | Mobile | Alabama | — | — |
| 502.476.061 Boehringer Ingelheim Investigational Site | Glendale | Arizona | — | — |
| 502.476.066 Boehringer Ingelheim Investigational Site | Carlisle | Arkansas | — | — |
| 502.476.067 Boehringer Ingelheim Investigational Site | Buena Park | California | — | — |
| 502.476.086 Boehringer Ingelheim Investigational Site | Encinitas | California | — | — |
| 502.476.124 Boehringer Ingelheim Investigational Site | Greenbrae | California | — | — |
| 502.476.005 Boehringer Ingelheim Investigational Site | Long Beach | California | — | — |
| 502.476.024 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 502.476.029 Boehringer Ingelheim Investigational Site | Redondo Beach | California | — | — |
| 502.476.048 Boehringer Ingelheim Investigational Site | Riverside | California | — | — |
| 502.476.073 Boehringer Ingelheim Investigational Site | Sacramento | California | — | — |
| 502.476.087 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 502.476.111 Boehringer Ingelheim Investigational Site | San Francisco | California | — | — |
| 502.476.050 Boehringer Ingelheim Investigational Site | Santa Ana | California | — | — |
| 502.476.026 Boehringer Ingelheim Investigational Site | Spring Valley | California | — | — |
| 502.476.033 Boehringer Ingelheim Investigational Site | Tulsa | California | — | — |
| 502.476.019 Boehringer Ingelheim Investigational Site | Boulder | Colorado | — | — |
| 502.476.101 Boehringer Ingelheim Investigational Site | Highlands Ranch | Colorado | — | — |
| 502.476.053 Boehringer Ingelheim Investigational Site | Farmington | Connecticut | — | — |
| 502.476.032 Boehringer Ingelheim Investigational Site | Newark | Delaware | — | — |
| 502.476.041 Boehringer Ingelheim Investigational Site | Coral Gables | Florida | — | — |
| 502.476.108 Boehringer Ingelheim Investigational Site | DeLand | Florida | — | — |
| 502.476.015 Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | — | — |
| 502.476.044 Boehringer Ingelheim Investigational Site | Hollywood | Florida | — | — |
| 502.476.058 FPA Clinical Research | Kissimmee | Florida | — | — |
| 502.476.052 Boehringer Ingelheim Investigational Site | Largo | Florida | — | — |
| 502.476.080 Boehringer Ingelheim Investigational Site | Melbourne | Florida | — | — |
| 502.476.021 Boehringer Ingelheim Investigational Site | Panama City | Florida | — | — |
| 502.476.012 Boehringer Ingelheim Investigational Site | Pembroke Pines | Florida | — | — |
| 502.476.036 Boehringer Ingelheim Investigational Site | Pembroke Pines | Florida | — | — |
| 502.476.065 Boehringer Ingelheim Investigational Site | Pembroke Pines | Florida | — | — |
| 502.476.022 Boehringer Ingelheim Investigational Site | Atlanta | Georgia | — | — |
| 502.476.049 Boehringer Ingelheim Investigational Site | Atlanta | Georgia | — | — |
| 502.476.008 Boehringer Ingelheim Investigational Site | Conyers | Georgia | — | — |
| 502.476.075 Boehringer Ingelheim Investigational Site | Decatur | Georgia | — | — |
| 502.476.018 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 502.476.047 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 502.476.004 Boehringer Ingelheim Investigational Site | Peoria | Illinois | — | — |
| 502.476.062 Boehringer Ingelheim Investigational Site | Evansville | Indiana | — | — |
| 502.476.063 Boehringer Ingelheim Investigational Site | Evansville | Indiana | — | — |
| 502.476.051 Boehringer Ingelheim Investigational Site | Indianapolis | Indiana | — | — |
| 502.476.084 Boehringer Ingelheim Investigational Site | South Bend | Indiana | — | — |
| 502.476.090 Boehringer Ingelheim Investigational Site | South Bend | Indiana | — | — |
| 502.476.100 Boehringer Ingelheim Investigational Site | Newton | Kansas | — | — |
| 502.476.003 Boehringer Ingelheim Investigational Site | Wichita | Kansas | — | — |
| 502.476.038 Boehringer Ingelheim Investigational Site | Wichita | Kansas | — | — |
| 502.476.002 Boehringer Ingelheim Investigational Site | Louisville | Kentucky | — | — |
| 502.476.116 Boehringer Ingelheim Investigational Site | New Orleans | Louisiana | — | — |
| 502.476.035 Boehringer Ingelheim Investigational Site | Oxon Hill | Maryland | — | — |
| 502.476.010 Boehringer Ingelheim Investigational Site | Troy | Michigan | — | — |
| 502.476.028 Boehringer Ingelheim Investigational Site | Brooklyn Center | Minnesota | — | — |
| 502.476.057 Boehringer Ingelheim Investigational Site | Edina | Minnesota | — | — |
| 502.476.055 Boehringer Ingelheim Investigational Site | Kansas City | Missouri | — | — |
| 502.476.114 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 502.476.112 Boehringer Ingelheim Investigational Site | Omaha | Nebraska | — | — |
| 502.476.126 Boehringer Ingelheim Investigational Site | Omaha | Nebraska | — | — |
| 502.476.125 Boehringer Ingelheim Investigational Site | Las Vegas | Nevada | — | — |
| 502.476.120 Boehringer Ingelheim Investigational Site | Berlin | New Jersey | — | — |
| 502.476.088 Boehringer Ingelheim Investigational Site | Ship Bottom | New Jersey | — | — |
| 502.476.089 Boehringer Ingelheim Investigational Site | Turnersville | New Jersey | — | — |
| 502.476.068 Boehringer Ingelheim Investigational Site | Brooklyn | New York | — | — |
| 502.476.122 Boehringer Ingelheim Investigational Site | Hamburg | New York | — | — |
| 502.476.020 Boehringer Ingelheim Investigational Site | Northport | New York | — | — |
| 502.476.025 Boehringer Ingelheim Investigational Site | Rochester | New York | — | — |
| 502.476.091 Boehringer Ingelheim Investigational Site | Williamsville | New York | — | — |
| 502.476.046 Boehringer Ingelheim Investigational Site | Burlington | North Carolina | — | — |
| 502.476.083 Boehringer Ingelheim Investigational Site | Charlotte | North Carolina | — | — |
| 502.476.042 Boehringer Ingelheim Investigational Site | Raleigh | North Carolina | — | — |
| 502.476.095 Boehringer Ingelheim Investigational Site | Salisbury | North Carolina | — | — |
| 502.476.027 Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| 502.476.034 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 502.476.060 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 502.476.016 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 502.476.023 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 502.476.128 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 502.476.064 Boehringer Ingelheim Investigational Site | Kettering | Ohio | — | — |
| 502.476.103 Boehringer Ingelheim Investigational Site | Olmsted Falls | Ohio | — | — |
| 502.476.007 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 502.476.113 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 502.476.030 Boehringer Ingelheim Investigational Site | Tulsa | Oklahoma | — | — |
| 502.476.104 Boehringer Ingelheim Investigational Site | Portland | Oregon | — | — |
| 502.476.109 Boehringer Ingelheim Investigational Site | Erie | Pennsylvania | — | — |
| 502.476.094 Boehringer Ingelheim Investigational Site | Harleysville | Pennsylvania | — | — |
| 502.476.121 Boehringer Ingelheim Investigational Site | Penndel | Pennsylvania | — | — |
| 502.476.072 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 502.476.076 Boehringer Ingelheim Investigational Site | Springfield | Pennsylvania | — | — |
| 502.476.013 Boehringer Ingelheim Investigational Site | East Providence | Rhode Island | — | — |
| 502.476.085 Boehringer Ingelheim Investigational Site | Cordova | Tennessee | — | — |
| 502.476.096 Boehringer Ingelheim Investigational Site | Jackson | Tennessee | — | — |
| 502.476.081 Boehringer Ingelheim Investigational Site | New Tazewell | Tennessee | — | — |
| 502.476.082 Boehringer Ingelheim Investigational Site | Selmer | Tennessee | — | — |
| 502.476.039 Boehringer Ingelheim Investigational Site | Carrollton | Texas | — | — |
| 502.476.056 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 502.476.069 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 502.476.107 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 502.476.070 Boehringer Ingelheim Investigational Site | Killeen | Texas | — | — |
| 502.476.001 Boehringer Ingelheim Investigational Site | Bountiful | Utah | — | — |
| 502.476.006 Boehringer Ingelheim Investigational Site | Salt Lake City | Utah | — | — |
| 502.476.017 Boehringer Ingelheim Investigational Site | Salt Lake City | Utah | — | — |
| 502.476.097 Boehringer Ingelheim Investigational Site | Sandy City | Utah | — | — |
| 502.476.098 Boehringer Ingelheim Investigational Site | Sandy City | Utah | — | — |
| 502.476.011 Boehringer Ingelheim Investigational Site | Falls Church | Virginia | — | — |
| 502.476.093 Boehringer Ingelheim Investigational Site | Norfolk | Virginia | — | — |
| 502.476.078 Boehringer Ingelheim Investigational Site | Tacoma | Washington | — | — |
| 502.476.106 Boehringer Ingelheim Investigational Site | Menomonee Falls | Wisconsin | — | — |
| 502.476.105 Boehringer Ingelheim Investigational Site | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00168779, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 28, 2017 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00168779 live on ClinicalTrials.gov.